Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope
暂无分享,去创建一个
M. Orozco | A. Scott | E. Lindahl | W. Cavenee | F. Furnari | Adam Hospital | P. Bernadó | T. Cordeiro | I. Brun-Heath | Laura Orellana | A. Thorne | Rafael Lema | Johan Gustavsson | Alison D. Parisian | A. H. Thorne
[1] Erik Lindahl,et al. eBDIMS server: protein transition pathways with ensemble analysis in 2D-motion spaces , 2019, Bioinform..
[2] Laura C. Zanetti-Domingues,et al. The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers , 2018, Nature Communications.
[3] L. Pike,et al. Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors , 2018, The Journal of Biological Chemistry.
[4] Christos Davatzikos,et al. Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. , 2018, Cancer cell.
[5] Franca Fraternali,et al. Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface , 2018, eLife.
[6] Quan Zhang,et al. The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer , 2017, Scientific Reports.
[7] Modesto Orozco,et al. Prediction and validation of protein intermediate states from structurally rich ensembles and coarse-grained simulations , 2016, Nature Communications.
[8] N. Jura,et al. Structural Basis for the Non-catalytic Functions of Protein Kinases. , 2016, Structure.
[9] R. Roskoski. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. , 2016, Pharmacological research.
[10] Xionglei He,et al. The Convergent Cancer Evolution toward a Single Cellular Destination. , 2016, Molecular biology and evolution.
[11] I. Maruyama. Activation of transmembrane cell‐surface receptors via a common mechanism? The “rotation model” , 2015, BioEssays : news and reviews in molecular, cellular and developmental biology.
[12] A. Schepartz,et al. Growth Factor Identity Is Encoded by Discrete Coiled-Coil Rotamers in the EGFR Juxtamembrane Region. , 2015, Chemistry & biology.
[13] M. Lemmon,et al. Ligand regulation of a constitutively dimeric EGF receptor , 2015, Nature Communications.
[14] T. Cloughesy,et al. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma , 2015, Nature Reviews Cancer.
[15] M. Lemmon,et al. Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor. , 2014, Cell reports.
[16] D. Shaw,et al. How IGF-1 activates its receptor , 2014, eLife.
[17] J. C. Love,et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. , 2014, Cancer discovery.
[18] Y. Mao,et al. Association of epithelial-mesenchymal transition with lapatinib resistance through multipe pathways activation in HER2-positive breast cancer. , 2014 .
[19] T. Walz,et al. Mechanisms for Kinase-mediated Dimerization of the Epidermal Growth Factor Receptor* , 2012, The Journal of Biological Chemistry.
[20] A. Scott,et al. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. , 2012, Cancer research.
[21] Paul S Mischel,et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. , 2012, Cancer discovery.
[22] D. Tindall,et al. Abstract 2924: Constitutively active androgen receptor splice variants function independently of full-length androgen receptor in a cell-based model of castrate-resistant prostate cancer , 2012 .
[23] F. Bosch,et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.
[24] C. Eigenbrot,et al. The ErbB4 extracellular region retains a tethered‐like conformation in the absence of the tether , 2012, Protein science : a publication of the Protein Society.
[25] Kwangsoo Kim,et al. Mechanistic Insights into the Activation of Oncogenic Forms of EGF Receptor , 2011, Nature Structural &Molecular Biology.
[26] Thomas Walz,et al. Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor , 2011, Nature Structural &Molecular Biology.
[27] A. Scott,et al. Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation , 2011, Cancers.
[28] T. Fenton,et al. Chinese Journal of Cancer , 2022 .
[29] Modesto Orozco,et al. Coarse-grained representation of protein flexibility. Foundations, successes, and shortcomings. , 2011, Advances in protein chemistry and structural biology.
[30] Shigeyuki Yokoyama,et al. Structural Evidence for Loose Linkage between Ligand Binding and Kinase Activation in the Epidermal Growth Factor Receptor , 2010, Molecular and Cellular Biology.
[31] Forest M White,et al. Oncogenic EGFR Signaling Networks in Glioma , 2009, Science Signaling.
[32] Webster K. Cavenee,et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR , 2009, Proceedings of the National Academy of Sciences.
[33] M. Lemmon,et al. Ligand-induced structural transitions in ErbB receptor extracellular domains. , 2007, Structure.
[34] S. Hubbard,et al. Receptor tyrosine kinases: mechanisms of activation and signaling. , 2007, Current opinion in cell biology.
[35] A. Scott,et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors , 2007, Proceedings of the National Academy of Sciences.
[36] S. Gabriel,et al. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.
[37] Gerd Ritter,et al. The antitumor monoclonal antibody 806 recognizes a high‐mannose form of the EGF receptor that reaches the cell surface when cells over‐express the receptor , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] K Dane Wittrup,et al. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. , 2004, Journal of molecular biology.
[39] K Dane Wittrup,et al. Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor* , 2004, Journal of Biological Chemistry.
[40] Nathan E Hall,et al. CR1/CR2 Interactions Modulate the Functions of the Cell Surface Epidermal Growth Factor Receptor* , 2004, Journal of Biological Chemistry.
[41] Peter Klein,et al. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[42] D. Leahy. Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors. , 2004, Advances in protein chemistry.
[43] A. Scott,et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[44] Hyun-soo Cho,et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.
[45] A. Scott,et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[46] A. Scott,et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. , 2001, Cancer research.